The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
P-glycoprotein Inhibition for Optimal Drug Delivery
Open accessAbstract
P-glycoprotein (P-gp), an efflux membrane transporter, is widely distributed throughout the body and is responsible for limiting cellular uptake and the distribution of xenobiotics and toxic substances. Hundreds of structurally diverse therapeutic agents are substrates to it and it impedes the absorption, permeability, and retention of the drugs, extruding them out of the cells. It is overexpressed in cancer cells and accountable for obstructing cell internalization of chemotherapeutic agents and for developing transporter mediated resistance by cancer cells during anti-tumor treatments. As it jeopardizes the success of drug delivery and cancer targeting, strategies are being developed to overcome P-gp mediated drug transport. This concise review represents a brief discussion on P-gp mediated drug transport and how it hinders the success of various therapies. Its main focus is on various strategies used to tackle this curb in the field of drug delivery and targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Efflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Phosphatidylcholine translocase: A physiological role for the mdr2 gene
Ruetz, S. (1994) · Cell · doi:10.1016/0092-8674(94)90446-4 · Cited by 599
Mechanisms of bacterial biocide and antibiotic resistance: ANTIBIOTIC AND BIOCIDE RESISTANCE
Poole, K. (2002) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.92.5s1.8.x · Cited by 513
The P-glycoprotein multidrug transporter
Sharom, F. J. (2011) · Essays in Biochemistry · doi:10.1042/bse0500161 · Cited by 509
Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., & Gabizón, A. (2000) · PubMed · Cited by 468
Cited by
Getting Across the Cell Membrane: An Overview for Small Molecules, Peptides, and Proteins
Yang, N. J., & Hinner, M. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2272-7_3 · Cited by 826
Superparamagnetic Iron Oxide Nanoparticles—Current and Prospective Medical Applications
Dulińska-Litewka, J., Łazarczyk, A., Hałubiec, P., Szafrański, O., Karnas, K., & Karewicz, A. (2019) · Materials · doi:10.3390/ma12040617 · Cited by 580
Materials for oral delivery of proteins and peptides
Brown, T. D., Whitehead, K. A., & Mitragotri, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0156-6 · Cited by 520
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
He, Q., Liu, J., Liang, J., Liu, X., Li, W., Liu, Z., Ding, Z., & Tuo, D. (2018) · Cells · doi:10.3390/cells7040024 · Cited by 298
Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors
Hettiarachchi, S. D., Graham, R. M., Mintz, K. J., Zhou, Y., Vanni, S., Peng, Z., & Leblanc, R. M. (2019) · Nanoscale · doi:10.1039/c8nr08970a · Cited by 294
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Zhang, H., Xu, H., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Liu, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21739 · Cited by 270
Morin: A Promising Natural Drug
Caselli, A., Cirri, P., Santi, A., & Paoli, P. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160106150821 · Cited by 253
Nanotechnology in Cancer Drug Delivery and Selective Targeting
Sutradhar, K. B., & Amin, M. L. (2014) · ISRN Nanotechnology · doi:10.1155/2014/939378 · Cited by 241
Self-citationPluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Tiwari, P., Yadav, K., Shukla, R. P., Gautam, S., Marwaha, D., Sharma, M., & Mishra, P. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.016 · Cited by 88
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
Schifano, F., & Chiappini, S. (2018) · PLOS ONE · doi:10.1371/journal.pone.0204443 · Cited by 44
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
Lima, T. S., Souza, L. O., Iglesias-Gato, D., Elversang, J., Jørgensen, F. S., Kallunki, T., Røder, M. A., Brasso, K., & Moreira, J. M. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869461 · Cited by 26
“Inhibition of ABCB1 efflux activity has been shown to reverse the MDR phenotype in model systems (Amin, 2013; Kadioglu et al., 2016), but clinical development of ABCB1 inhibitors has been largely unsuccessful, primarily due to lack of efficacy and/or development of severe side effects (Shukla et al.”
BackgroundMonton, C., Chankana, N., Leelawat, S., Suksaeree, J., & Songsak, T. (2022) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2021.105423 · Cited by 25
Ghadi, M., Hosseinimehr, S. J., Amiri, F. T., Mardanshahi, A., & Noaparast, Z. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173892 · Cited by 17
Metadata
- Authors
- Amin, M. L.
- Venue
- Drug Target Insights
- Publisher
- Aboutscience Srl
- Published
- 2013-01
- Volume
- 7
- Pages
- DTI.S12519
- ISSN
- 1177-3928 (ISSN-L)
- OpenAlex
- W2032222317
- Cited by
- 624
- References
- 51
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.